Investors prefer clean stories. Combination protocols do not offer them. A GLP-1 agent has a defined label, a reimbursement pathway, and a measurable market. Add a peptide or a hormone, and the narrative fractures. Revenue attribution becomes ambiguous. So does regulatory risk. Clinical studies offer partial anchors. Weight-loss trials establish efficacy for incretins. Hormone replacement literature—summarized in parts by analyses available through https://pubmed.ncbi.nlm.nih.gov—documents effects on body composition and metabolic parameters. But capital markets discount combinations because the pathways to approval are less direct. There is also a compression effect. If a combination protocol delivers multiple outcomes—weight loss, improved glycemic control, shifts in lipids, changes in body composition—it potentially displaces multiple therapeutic categories. That is efficient for patients. It is disruptive for portfolios. Pricing becomes unstable. Should a combined regimen be priced as the sum of its parts, or as a new category? Payers resist aggregation. Manufacturers prefer differentiation.
The
tension is unresolved. Trial design lags the practice. Adaptive trials could, in theory, test sequences and combinations. In practice, most programs remain monotherapy-focused. The data therefore underestimate interaction effects—positive or negative. Second-order effects extend beyond revenue. If lean mass preservation becomes a recognized endpoint, device markets—from imaging to strength assessment—may expand. If adherence falls with complexity, digital support layers become more valuable. Each shift creates adjacent opportunities and risks. There is a temptation to view combinations as incremental. They are not. They alter the topology of the market. The map is still being drawn. Investors prefer clean stories. Combination protocols do not offer them. A GLP-1 agent has a defined label, a reimbursement pathway, and a measurable market. Add a peptide or a hormone, and the narrative fractures. Revenue attribution becomes ambiguous. So does regulatory risk. Clinical studies offer partial anchors. Weight-loss trials establish efficacy for incretins. Hormone
replacement literature—summarized in parts by analyses available through https://pubmed.ncbi.nlm.nih.gov—documents effects on body composition and metabolic parameters. But capital markets discount combinations because the pathways to approval are less direct. There is also a compression effect. If a combination protocol delivers multiple outcomes—weight loss, improved glycemic control, shifts in lipids, changes in body composition—it potentially displaces multiple therapeutic categories. That is efficient for patients. It is disruptive for portfolios. Pricing becomes unstable. Should a combined regimen be priced as the sum of its parts, or as a new category? Payers resist aggregation. Manufacturers prefer differentiation. The tension is unresolved. Trial design lags the practice. Adaptive trials could, in theory, test sequences and combinations. In practice, most programs remain monotherapy-focused. The data therefore underestimate interaction effects—positive or negative. Second-order effects extend beyond revenue. If lean mass preservation becomes a recognized endpoint, device markets—from imaging to strength assessment—may expand. If adherence
falls with complexity, digital support layers become more valuable. Each shift creates adjacent opportunities and risks. There is a temptation to view combinations as incremental. They are not. They alter the topology of the market. The map is still being drawn. Investors prefer clean stories. Combination protocols do not offer them. A GLP-1 agent has a defined label, a reimbursement pathway, and a measurable market. Add a peptide or a hormone, and the narrative fractures. Revenue attribution becomes ambiguous. So does regulatory risk. Clinical studies offer partial anchors. Weight-loss trials establish efficacy for incretins. Hormone replacement literature—summarized in parts by analyses available through https://pubmed.ncbi.nlm.nih.gov—documents effects on body composition and metabolic parameters. But capital markets discount combinations because the pathways to approval are less direct. There is also a compression effect. If a combination protocol delivers multiple outcomes—weight loss, improved glycemic control, shifts in lipids, changes in body composition—it
potentially displaces multiple therapeutic categories. That is efficient for patients. It is disruptive for portfolios. Pricing becomes unstable. Should a combined regimen be priced as the sum of its parts, or as a new category? Payers resist aggregation. Manufacturers prefer differentiation. The tension is unresolved. Trial design lags the practice. Adaptive trials could, in theory, test sequences and combinations. In practice, most programs remain monotherapy-focused. The data therefore underestimate interaction effects—positive or negative. Second-order effects extend beyond revenue. If lean mass preservation becomes a recognized endpoint, device markets—from imaging to strength assessment—may expand. If adherence falls with complexity, digital support layers become more valuable. Each shift creates adjacent opportunities and risks. There is a temptation to view combinations as incremental. They are not. They alter the topology of the market. The map is still being drawn. Investors prefer clean stories. Combination protocols do not offer them. A GLP-1
agent has a defined label, a reimbursement pathway, and a measurable market. Add a peptide or a hormone, and the narrative fractures. Revenue attribution becomes ambiguous. So does regulatory risk. Clinical studies offer partial anchors. Weight-loss trials establish efficacy for incretins. Hormone replacement literature—summarized in parts by analyses available through https://pubmed.ncbi.nlm.nih.gov—documents effects on body composition and metabolic parameters. But capital markets discount combinations because the pathways to approval are less direct. There is also a compression effect. If a combination protocol delivers multiple outcomes—weight loss, improved glycemic control, shifts in lipids, changes in body composition—it potentially displaces multiple therapeutic categories. That is efficient for patients. It is disruptive for portfolios. Pricing becomes unstable. Should a combined regimen be priced as the sum of its parts, or as a new category? Payers resist aggregation. Manufacturers prefer differentiation. The tension is unresolved. Trial design lags the practice. Adaptive trials could,
in theory, test sequences and combinations. In practice, most programs remain monotherapy-focused. The data therefore underestimate interaction effects—positive or negative. Second-order effects extend beyond revenue. If lean mass preservation becomes a recognized endpoint, device markets—from imaging to strength assessment—may expand. If adherence falls with complexity, digital support layers become more valuable. Each shift creates adjacent opportunities and risks. There is a temptation to view combinations as incremental. They are not. They alter the topology of the market. The map is still being drawn. Investors prefer clean stories. Combination protocols do not offer them. A GLP-1 agent has a defined label, a reimbursement pathway, and a measurable market. Add a peptide or a hormone, and the narrative fractures. Revenue attribution becomes ambiguous. So does regulatory risk. Clinical studies offer partial anchors. Weight-loss trials establish efficacy for incretins. Hormone replacement literature—summarized in parts by analyses available through https://pubmed.ncbi.nlm.nih.gov—documents effects on
body composition and metabolic parameters. But capital markets discount combinations because the pathways to approval are less direct. There is also a compression effect. If a combination protocol delivers multiple outcomes—weight loss, improved glycemic control, shifts in lipids, changes in body composition—it potentially displaces multiple therapeutic categories. That is efficient for patients. It is disruptive for portfolios. Pricing becomes unstable. Should a combined regimen be priced as the sum of its parts, or as a new category? Payers resist aggregation. Manufacturers prefer differentiation. The tension is unresolved. Trial design lags the practice. Adaptive trials could, in theory, test sequences and combinations. In practice, most programs remain monotherapy-focused. The data therefore underestimate interaction effects—positive or negative. Second-order effects extend beyond revenue. If lean mass preservation becomes a recognized endpoint, device markets—from imaging to strength assessment—may expand. If adherence falls with complexity, digital support layers become more valuable. Each shift
creates adjacent opportunities and risks. There is a temptation to view combinations as incremental. They are not. They alter the topology of the market. The map is still being drawn. Investors prefer clean stories. Combination protocols do not offer them. A GLP-1 agent has a defined label, a reimbursement pathway, and a measurable market. Add a peptide or a hormone, and the narrative fractures. Revenue attribution becomes ambiguous. So does regulatory risk. Clinical studies offer partial anchors. Weight-loss trials establish efficacy for incretins. Hormone replacement literature—summarized in parts by analyses available through https://pubmed.ncbi.nlm.nih.gov—documents effects on body composition and metabolic parameters. But capital markets discount combinations because the pathways to approval are less direct. There is also a compression effect. If a combination protocol delivers multiple outcomes—weight loss, improved glycemic control, shifts in lipids, changes in body composition—it potentially displaces multiple therapeutic categories. That is efficient for patients.
